Company intelligence / Profile preview

Hangzhou Endonom Medtech

Hangzhou, Zhejiang, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Hangzhou Endonom Medtech develops advanced cardiovascular medical devices, with its lead program being the WeFlow-Tbranch Stent Graft System for complex thoracic aortic and arch reconstructions. The company's pipeline includes three late-stage products focused on cardiovascular intervention and wound care management. Clinical studies are ongoing to evaluate safety and efficacy in major Chinese centers, indicating strong progress toward commercialization.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Hangzhou Endonom Medtech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Endonom Medtech.

Explore the full profile